Compare Abbott Laboratories (ABT) vs ServiceNow Inc (NOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs ServiceNow Inc — how do they compare? Abbott Laboratories trades at $109.56 (market cap $187.95B), while ServiceNow Inc trades at $123.53 (market cap $131.86B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays a 2.32% dividend while ServiceNow Inc pays none. Which is the better fit depends on your goals.
| ABT | NOW | |
|---|---|---|
Market Cap | $187.95B | $131.86B |
Sector | Health | Technology |
52-Week High | $136.62 | $192.23 |
52-Week Low | $82.57 | $83.00 |
Enterprise Value | $214.96B | $135.65B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
ServiceNow (NOW) trades at $127.44, up 2.05% today, with a bullish technical outlook supported by moving averages but overbought RSI signals. Revenue grew to $13.28B in 2025, with a net income margin of 11.34%, though high P/E of 79.71 indicates premium valuation. Recent news highlights AI-driven growth opportunities, including partnerships and conference presentations in June 2026.
The stock offers growth potential from AI adoption and strong cash flows, but faces risks from elevated valuations and competitive pressures. Analyst consensus is strongly bullish with an average price target of $138.26, though investors should monitor earnings consistency and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
